Furthermore, in a trial for recurrent ovarian cancer, a high CD40 gene signature was a key feature in patients achieving durable clinical benefit from immunotherapy [27], linking high CD40 expression to an immunologically “hot” state permissive for response. The gene discussed is CD40; the disease is ovarian carcinoma.